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Background: COPD is characterized by a multi-component character involving a state of low-
grade systemic inflammation and an increased prevalence of cardiovascular co-morbidity.
The role of circulating leptin and other adipokines in the involvement of the systemic inflam-
mation in COPD is only studied scarcely.
Objective: To investigate gender related differences in the adipokine metabolism in relation
to systemic inflammatory biomarkers in clinically stable subjects with COPD.
Methods: In total, 91 clinically stable COPD patients and 35 healthy control subjects, matched
for body mass index (BMI) with the COPD subjects, were included. Lung function measurement
and body composition were performed in patients with COPD. In the total group, plasma
concentration of the adipokines (leptin, adiponectin and resistin) and systemic inflammatory
biomarkers C-reactive protein (CRP), interleukin 6 (IL-6), tumor necrosis factor a (TNFa),
and its soluble receptors 55 and 75 (sTNFa-R55, R75) were analyzed.of Respiratory Medicine, Maastricht University Medical Centreþ (MUMCþ), P.O. Box 5800, 6202 AZ
1 43 38750 44; fax: þ31 43 38750 51.
.at (M.-K. Breyer).
r more details see Appendix section.
1 Elsevier Ltd. All rights reserved.
Gender differences of leptin in COPD 1047Results: The COPD group was characterized by increased levels of CRP, IL-6 and leptin. Plasma
adiponectin and resistin concentrations were not different between the COPD and the control
group. Within the COPD group, there was a significant interaction between gender and BMI on
the leptin/fat mass ratio. In COPD women, a significant correlation between leptin and CRP
was present.
Conclusions: In men with clinically stable COPD, leptin, adiponectin and resistin appear to be
physiologically regulated, while in women, leptin metabolism is altered. Leptin secretion is
increased in COPD women when compared to healthy women and compared to COPD men, and
to a greater extent in overweight women with COPD.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD), a disease
characterized by partially reversible airflow limitation, is
usually progressive and associated with an abnormal
inflammatory response of the lung to noxious particles or
gases.1 Furthermore, COPD is these days recognized as
a multi-component disease, involving various extra-pulmo-
nary manifestations like low-grade systemic inflammation
and an increased prevalence of cardiovascular co-
morbidity.2 Worldwide attention has been focused on
COPD, as COPD is predicted to become the third leading
cause of death worldwide by the year 2020 [1]. Since recent
years, the prevalence of COPD in women has been
increasing, and the question arises if the nature of the
biologic injury differs between COPD men and women.3
Various gender differences are recognized in COPD, as
women exhibit anatomically smaller airway lumens and
they suffer from less extensive emphysema.4 In addition,
women with COPD experience more symptoms of depres-
sion compared to male,5 and clinical data suggest sex
hormones affecting airway function.6
Gender related differences in the extra-pulmonary
manifestation of COPD are barely investigated. Interest-
ingly, a recent study showed that systemic effects of
smoking differ between men and women.7 The authors
demonstrated decreased plasma concentrations of the anti-
inflammatory adipokine adiponectin in women. In addition,
the same authors reported increased plasma levels of high
sensitive C-reactive protein (CRP) in men.7 These differ-
ences may contribute to a different etiology of extra-
pulmonary manifestations of COPD among men and women.
Circulating leptin is originally described as an adipocyte-
derived hormone involved in the processes of limiting food
intake, increasing energy expenditure and decreasing
metabolic efficiency by activating its functional receptor
(Ob-Rb) in the hypothalamus.8 Hereby, leptin is positively
linked with body mass index (BMI; weight in kilograms
divided by squared height in meters) and fat mass. The
structure of leptin and its receptor classify leptin as a type I
cytokine, increasing acutely by inflammatory and infectious
stimuli, such as tumor necrosis factor (TNF)a and lipo-
polysaccharide9 In general, circulating leptin levels have
been shown to be positively related to cardiovascular
disease10,11 and in addition are gender related and higher in
healthy women compared to healthy men, independent of
BMI. Indeed, for the same amount of fat mass, women have
higher circulating leptin levels compared to men.12 The roleof circulating leptin and other adipokines in the involve-
ment of the systemic inflammation in COPD is only studied
scarcely and mainly in male COPD patients with a low BMI
(<21 kg/m2).13e16 From these studies, it is concluded that
circulating leptin plays a physiological role in COPD, even in
underweight patients.
The present study primarily aimed to unravel gender
related differences in the adipokine metabolism in clini-
cally stable subjects with COPD. Secondarily, we aimed to
compare plasma levels of adipokines (leptin, adiponectin
and resistin) with systemic inflammatory biomarkers, such
as CRP, interleukin 6 (IL-6), tumor necrosis factor a (TNFa),
and its soluble receptors 55 and 75 (sTNFa-R55, R75) in
COPD and in healthy control subjects.
Materials and methods
Study population
Data were collected from 91 subjects with COPD, stratified
in 4 groups by BMI and matched for age, gender and
disease severity. All patients were entering pulmonary
rehabilitation at the Centre of expertise for chronic organ
failure (Ciro), Horn, the Netherlands. Patients were
excluded, if they had an exacerbation within the last 4
weeks before study entry. All patients were free of taking
oral corticosteroids or antibiotics. Other current medica-
tion use was recorded, particularly the use of inhaled
corticosteroids, and any anti-inflammatory medication,
particularly NSAR, and statins. The control group is
composed of 35 Caucasian non-diabetic genetically inde-
pendent subjects. They were extracted from the spouses
databank of Familial Combined Hyperlipidemia families.
The study protocol has been described in detail else-
where.17 Any lipid-lowering medication had been with-
drawn during the last 2 weeks before blood sampling. The
healthy subjects were age and BMI matched with the COPD
patients. The Medical Ethical Committee of the University
Hospital Maastricht approved the study, and all subjects
gave written informed consent.
Lung function, arterial blood gases and body
composition in the subjects with COPD
In all patients, lung function parameters were collected
using standardized spirometry (Masterlab, Viasys,
Germany). The degree of severity of airflow limitation was
classified according to the GOLD guidelines (GOLD stage 1:
1048 M.-K. Breyer et al.FEV1/FVC< 70% and FEV1> 80% of the predicted values;
GOLD stage 2: FEV1/FVC< 70% and FEV1 between 80 and
50% of the predicted values; GOLD stage 3: FEV1/FVC< 70%
and FEV1 between 50 and 30% of the predicted values; and
GOLD stage 4: FEV1/FVC< 70% and FEV1< 30% of the pre-
dicted values or FEV1< 50% of the predicted values plus
chronic respiratory failure).1 Arterial oxygen tension (PaO2)
and arterial carbon dioxide tension (PaCO2) were measured
while patients were breathing room air or when on long
term oxygen therapy (LTOT; nZ 4) when breathing oxygen
and have been analyzed with a blood gas analyzer (ABL 700,
Radiometer, Copenhagen, Denmark).
Body height was measured to the nearest 0.1 cm. Body
weight was assessed by using an electronic beam scale with
digital readout to the nearest 0.1 kg after emptying the
bladder and with the subjects standing barefoot and
wearing light indoor clothing. BMI was calculated as body
weight/height2 (kg/m2). A priori, BMI was categorized into
low (<21 kg/m2), normal (21e24.9 kg/m2), high
(25e29.9 kg/m2) and obese (30 kg/m2). Body composition
(fat free mass, FFM, and fat mass, FM) has been assessed
using an overnight-fasting bioelectrical impedance analysis
(Bodystat). FFM was calculated by using disease and
gender-specific equations.18 FFM index (FFMI) was calcu-
lated as FFM in kilogram divided by squared height in
meters. FFM depletion was defined as FFMI 15 (females)
and 16 (males) kg/m2.18 FM in kilogram was calculated as
total body weight minus FFM. Additionally, patients’
smoking status (never, former, current smoker), amount of
packs smoked per year (PY) and patients’ co-morbidities
were recorded.
Blood sample analyses
Blood sampling occurred after overnight fast. In all partic-
ipants blood samples were analyzed with the same, most
recent available kits. HsCRP was assessed in duplicate by
high-sensitivity particle-enhanced immunoassay (COBAS
Micra, Radiometer, Copenhagen, Denmark). IL-6 was
determined with the PeliKine CompactTM human IL-6 ELISA
kit (Sanquin Reagents, Amsterdam, the Netherlands).
Circulating leptin, adiponectin and resistin were assessedTable 1 Baseline characteristics of subjects with COPD.
Median (25the75th percentiles) Total (n Z 91)
Age, years 62.0 (55.0e70.0)
BMI, kg/m2 24.2 (20.6e29.4)
FMI, kg/m2 10.7 (8.56e12.5)
FFMI, kg/m2 15.7 (14.2e17.7)
FEV1, % predicted 40.0 (27.0e53.2)
FEV1/FVC 40.9 (32.9e48.0)
GOLD II, III, IV, % 35, 36, 29
PaO2, kPa 9.10 (8.20e10.3)
PaCO2, kPa 5.30 (5.00e5.90)
Smoking status, n (%)
Never smoker 1 (1)
Former smoker 65 (72)
Current smoker 25 (27)
Pack years 40 (30e46)
BMI, body mass index; FMI, fat mass index; FFMI, fat free mass index;using a human leptin ELISA, a human high-sensitivity adi-
ponectin ELISA and a human resistin ELISA, respectively
(BioVendor, Brno, Czech Republic). TNFa was determined
using Qauntikine HS-human TNFa/NTFSF1A immunoassay
(R&D, Minneapolis, USA). ELISA kits for detection of the
sTNFa-R55 and sTNFa-R75 were purchased from HyCult
Biotechnology (Uden, the Netherlands). Detection limits of
the single assays were: 0.23 mg/l for hsCRP; 0.2 pg/ml for
IL-6; 1.5 ng/ml for leptin; 5 ng/ml for adiponectin; 1 mg/ml
for resistin; 0.5 pg/ml for TNFa; 16 pg/ml for both sTNFa-
R55 and sTNFa-R75. Only in 2 healthy control subjects,
levels of circulating leptin were below the defined lower
level of detection.
Statistical analyses
All analyses were performed using Statistical Package for the
Social Sciences (SPSS) version 15.01. for Windows. Metabolic
data of the COPD subjects were stratified for BMI. Cate-
gorical variables have been described as frequencies, while
continuous variables are presented as median and 25th to
75th percentile, due to their skewed distribution. Evaluation
of differences in continuous variables between two groups
was done using the non-parametric ManneWhitney U test,
while differences between more than two groups were
tested using the KruskaleWallis test. Categorical variables
were tested using the chi2-test. In addition, due to the high
degree of correlation between circulating leptin and total
body fat mass (r Z 0.79; p < 0.01), leptin to fat mass ratio
(leptin/FM) was created. The interaction between BMI and
gender on leptin/FM was tested by general linear model.
The Bonferroni correction was performed to correct for
multiple comparison. Spearman correlation coefficient was
calculated to test correlations between adipokines and
biomarkers for systemic inflammation in the COPD group. A
p-value of 0.05 was considered significant.
Results
On average, subjects with COPD had moderate to severe
COPD, a normal BMI, FFMI and normal arterial blood gases
(Table 1). In total, 80% of COPD patients inhaledMale (n Z 46) Female (n Z 45) p-value
65.5 (55.8e73.0) 59.0 (54.0e64.5) 0.013
23.5 (20.6e29.8) 24.8 (20.7e29.2) 0.694
8.93 (7.24e11.4) 12.0 (9.39e14.3) <0.01
16.5 (14.9e19.4) 14.9 (13.6e16.2) <0.01
40.6 (25.5e54.2) 30.0 (27.3e53.0) 0.877
40.3 (29.5e46.3) 41.5 (33.8e50.9) 0.446
37, 37, 26 33, 36, 31 0.610
9.15 (8.17e10.2) 9.10 (8.30e10.3) 0.946
5.30 (4.90e6.19) 5.40 (5.00e5.85) 0.921
0.959
0 1 (2)
34 (74) 31 (69)
12 (26) 13 (29)
40 (33e50) 38 (25e41) 0.011
FEV1, forced expiratory volume in 1s; FVC, forced vital capacity.
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Gender differences of leptin in COPD 1049corticosteroids and 40% were using any anti-inflammatory
medication. After stratification for gender, both men and
women with COPD showed normal BMI and arterial blood
gases. Age, FMI, FFMI, and the amount of PY were signifi-
cantly different between male and female COPD patients.
No differences were found in use of inhaled corticosteroids
or anti-inflammatory medication, after stratification for
gender.
When comparing subjects with COPD to healthy age
[median age: 60.0years (53.3e65.8, 25the75th percentile),
sex (67% male)], and BMI matched subjects [median BMI:
26.6 kg/m2 (23.1e29.5, 25the75th percentile)] significantly
higher levels of CRP, IL-6, and circulating leptin were found
in the COPD group (Table 2). After stratification for gender,
men with COPD had higher levels of CRP and IL-6 compared
to their healthy peers. Women with COPD had higher levels
of circulating leptin compared to their healthy peers. When
comparing men and women, men with COPD had lower
circulating levels of adiponectin and leptin and lower lep-
tin/FM compared to their female counterparts. Within the
healthy subjects, men showed lower levels of adiponectin
compared to women. There were no differences in plasma
concentration of TNFa, its soluble receptors R55 and R75,
and resistin between the groups.
Table 3 shows age, lung function parameters, pack
years, and plasma concentration of systemic inflammatory
biomarkers and adipokines in subjects with COPD after
stratification for gender and BMI. Age, the degree of lung
function impairment, the amount of PY, and the use of
inhaled corticosteroids and any anti-inflammatory medica-
tion were not different between the BMI strata, neither in
male nor in female. After correcting for these potential
confounders, there was a significant increase in CRP levels
toward higher BMI strata in women, and increased leptin
levels toward higher BMI strata for both men and women.
There was no difference in the levels of other systemic
inflammatory biomarkers and plasma adiponectin and
resistin levels among BMI strata. Leptin/FM for different
BMI categories and gender in COPD is shown in Fig. 1. In
both men and women, leptin/FM increased with increasing
BMI, and there was a significant interaction between gender
and BMI to a higher increase in the women with COPD
(p < 0.01).
When COPD subjects were stratified for gender, no
significant Spearman’s correlation coefficient was found
between plasma leptin and adiponectin concentration and
plasma CRP (p Z 0.721, p Z 0.647), IL-6 (p Z 0.745,
p Z 0.621), TNFa (p Z 0.332, p Z 0.449) and its soluble
receptors 55 (p Z 0.989, p Z 0.297) and 75 (p Z 0.514,
p Z 0.860) for men. For women, plasma leptin concen-
tration was significantly correlated with plasma CRP
concentration (r Z 0.40, p < 0.01). For both men and
women, plasma resistin concentration was significantly
correlated with CRP (r Z 0.23, p < 0.05), IL-6 (r Z 0.41,
p < 0.01), sTNFa-R55 (r Z 0.44, p < 0.01), and sTNFa-R75
(r Z 0.38, p < 0.01).
Discussion
The present study is the first that evaluated various adi-
pokines, such as leptin, adiponectin and resistin and
biomarkers of systemic inflammation in men and women
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Table 3 Age, lung function parameters, pack years, and plasma concentration of systemic inflammatory biomarkers and adipokines of subjects with COPD after stratification
for gender and BMI.
BMI, kg/m2 (n Z 91) Male (n Z 46); median (25the75th percentile) Female (n Z 45); median (25the75th percentile)
Low (n Z 14) Normal (n Z 12) High (n Z 9) Obese (n Z 11) Low (n Z 14) Normal (n Z 9) High (n Z 13) Obese (n Z 9)
Age, years 65 (55e73) 65 (60e77) 65 (56e69) 70 (54e73) 60 (52e63) 62 (57e70) 54 (53e62) 64 (57e71)
FEV1, % predicted 36.9 (20.1e56.1) 37.6 (26.3e53.5) 44.0 (28.6e51.9) 46.4 (27.0e64.6) 36.6 (24.7e53.5) 30.3 (22.1e56.7) 42.7 (29.2e50.4) 44.1 (32.3e63.3)
FEV1/FVC, % pred. 39.1 (31.4e44.1) 36.3 (27.0e44.6) 45.2 (37.7e52.9) 42.5 (29.3e51.4) 34.6 (30.4e46.1) 44.5 (33.9e56.9) 41.7 (37.9e49.9) 47.0 (31.4e51.3)
Pack years 42 (38e50) 38 (31e50) 45 (35e55) 35 (20e65) 40 (24e46) 40 (28e46) 30 (20e40) 34 (22e40)
CRP*, mg/l 4.74z (1.27e23.3) 3.51 (1.03e8.90) 3.17 (1.08e8.84) 5.75 (1.76e10.0) 1.45 (0.58e3.63) 4.17 (1.07e11.9) 2.55 (1.99e5.92) 9.00 (5.33e11.7)
IL-6, pg/ml 3.17 (1.39e10.3) 1.08 (0.42e2.50) 1.43 (1.32e4.97) 2.02 (1.15e3.55) 1.18 (0.54e2.63) 1.06 (0.90e4.73) 1.69 (1.10e2.30) 2.91 (1.42e3.92)
TNFa, pg/ml 1.95 (1.34e3.12) 1.35 (0.89e2.53) 1.72 (0.92e1.94) 1.53 (1.09e2.33) 1.18 (0.86e2.04) 1.42 (1.29e2.04) 1.66 (1.18e1.83) 2.03 (1.42e3.06)
sTNFa-R55, pg/ml 1.42 (1.20e1.71) 1.26 (0.95e1.64) 1.16 (0.96e1.83) 1.69 (1.09e2.27) 1.13 (0.90e1.75) 1.25 (1.07e1.91) 1.03 (0.89e1.37) 1.72 (1.2e2.56)
sTNFa-R75, pg/ml 1.59 (1.36e2.56) 1.42 (1.30e1.76) 1.54 (1.23e2.14) 2.11 (1.60e2.39) 1.32 (0.99e2.03) 1.59 (0.93e2.03) 1.35 (1.29e1.78) 2.09 (1.39e2.22)
Leptin*, ng/ml 3.00y (3.00e4.89) 8.02y (3.37e13.9) 18.8y (17.4e30.8) 37.9y (25.4e58.3) 15.9 (6.29e20.6) 40.3 (22.4e49.0) 64.7 (54.7e105) 150 (103e221)
Adiponectin, mg/ml 10.6 (6.48e14.8) 12.2 (5.80e17.3) 7.13 (4.32e8.67) 6.39 (5.68e11.2) 13.4 (8.26e20.1) 10.6 (6.15e16.5) 9.68 (5.4e14.8) 11.4 (8.33e16.3)
Resistin, ng/ml 8.54 (6.87e11.1) 11.4 (7.63e13.8) 6.87 (6.01e12.6) 9.57 (6.96e13.6) 7.78 (7.16e10.9) 10.0 (7.05e14.1) 9.27 (7.44e11.3) 9.98 (7.57e18.5)
FEV1, forced expiratory volume in 1s; FVC, forced vital capacity; BMI, body mass index; FM, fat mass; FMI, fat mass index; CRP, C-reactive protein; IL-6, Interleukin 6; TNFa, tumor necrosis
factor alpha; sTNFa-R55, soluble TNFa receptor 55; sTNFa-R75, soluble TNFa receptor 75.
*Significant trend (p < 0.01) for male and female COPD patients fr tients.
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Gender differences of leptin in COPD 1051the adipocyte induced systemic inflammation, which also
has been recently confirmed.21
The role of circulating leptin in the systemic manifes-
tation of COPD has gained attention as leptin is linked to
a pro-inflammatory state.22 However until now, studies
concerning circulating leptin concentration in clinically
stable subjects with COPD found no significant differences
in COPD and control subjects.23 Possible reasons might be
the limited number of patients included in these studies
and the fact that only males and/or underweight patients
were included. In the present study however, we showed
a significant interaction between gender and BMI. Circu-
lating leptin concentration was increased in overweight
women with COPD, even after correction for fat mass. The
cause for this phenomenon remains unclear. In the healthy
population, it is well recognized that women have higher
circulating leptin concentration compared to men.24
Women have a higher fat mass percentage than men,
resulting in higher circulating leptin secretion in women.
Moreover, animal and in vitro studies confirmed that
androgens have an inhibitory effect on circulating leptin
secretion, whereas estradiol has a stimulatory effect.25 Our
study population consists of women with a median age of 59
years, implying that most women are post-menopausal,
characterized by low estrogen levels. The changes in body
composition occurring after the menopause (increase of
body fat), induced by low estrogen concentrations, may
lead to higher circulating leptin secretion.26 It is therefore
tempting to speculate that overweight COPD women suffer
from an imbalance in sex hormones, which may explain the
increased circulating plasma leptin levels in this COPD
subgroup. Disturbances in the estrogen metabolism in
women with COPD are not investigated yet, although
estrogens are thought to be involved in the biological
difference in susceptibility of the development of COPD.27
No studies yet exist investigating the clinical outcomes
of increased leptin concentrations in women with COPD.
So, we can only speculate about possible consequences of
an increased circulating leptin concentration, as the
secretion of circulating leptin is an inter-player in the
complex adipose secretory system. Nevertheless, there is
evidence that leptin metabolism is linked to the inflam-
matory system, and in healthy, circulating leptin is more
associated with plasma CRP concentration in women than in
men.12 In the present study, circulating leptin correlated
with plasma CRP concentration in women with COPD, but
not in men. Furthermore, the association of weight gain on
systemic inflammation in subjects with COPD is higher in
women than in men,28 which is in line with the higher
circulating leptin concentration in women with COPD that
we found in our study. Moreover, circulating leptin was
correlated with total glutathione concentration in elderly
women, but neither in elderly men nor in younger peers.24
Higher glutathione concentration in elderly women can
favor systemic inflammation. As leptin is known to enhance
the production of reactive oxygen species by leukocytes,29
one could speculate that the increased leptin concentra-
tion in women with COPD is associated with increased
oxidative stress. Herewith inline, Sin et al. recently
proposed a mechanism by which women with COPD are
more susceptible to COPD via a disbalance in the oxidant/
anti-oxidant pathway.27 Whether the increased leptinconcentration in women with COPD per se is associated
with increased oxidative stress is not known yet, but COPD
is generally characterized by a reduced anti-oxidant
capacity and increased production of reactive oxygen
species.30 In healthy subjects, circulating leptin is a strong
predictor for first-ever hemorrhagic stroke and myocardial
infarction,10,11 suggesting that leptin is an important link in
the development of cardiovascular disease. In post-meno-
pausal women, circulating leptin is besides BMI a predictor
for insulin resistance.31 Whether women with COPD,
particularly those who are overweight, suffer from more
co-morbidities compared to their male counterparts is not
known yet. As the lung is highly vascularized, the increased
circulating levels of leptin may also contribute to the
pathogenesis of lung inflammation and injury in COPD.
Leptin is detectable in the pulmonary compartment32,33 of
COPD patients, and leptin levels in induced sputum showed
a positive correlation with those of CRP and TNFa.32 In
addition, we recently demonstrated that a functional leptin
signaling pathway is present in both bronchial and alveolar
epithelial cells,33 indicating that leptin may be involved in
the local inflammatory response in COPD. Further studies
are warranted to investigate this hypothesis.
Plasma adiponectin, a protein largely secreted from
adipose tissue, is known to increase fatty acid oxidation and
reduce the synthesis of glucose in the liver.34 Adiponectin
has various protective anti-inflammatory effects on the
metabolic derangements that may result in a lower risk for
the development of atherosclerosis and type 2 diabetes.35
Data about adiponectin concentration in patients with
COPD are scarce and with inconclusive results. In the
present study, circulating levels of adiponectin were higher
in women compared to men, and tended to decrease with
increasing BMI. These results are in consistence with
previous reports concerning healthy subjects,7 implying
a physiological role of adiponectin in this cohort of COPD
patients. Resistin is an adipocyte-derived protein that is
positively associated with insulin resistance in rodents and
humans.36 Furthermore, it seems to induce, and also being
induced by other pro-inflammatory cytokines, such as IL-6
and TNFa in humans.34 To date, limited data are available
on the exact role of resistin and the association of various
pathological conditions, such as an increased insulin sensi-
tivity, type 2 diabetes or factors related to the metabolic
syndrome.37 Data about levels of resistin in patients with
COPD are limited, and in the present study, levels of plasma
resistin concentration were not different between the COPD
group and their healthy peers. The association between
resistin and systemic inflammatory biomarkers found in the
present study was also confirmed by others,38 implying that
resistin is also physiologically regulated in clinically stable
patients with COPD.Limitations of the study
One limitation of the study might be the small sample size,
especially after stratifying the COPD patients into
subgroups. However, other studies investigating plasma
levels of adipokines in COPD patients have comparably
small sample sizes15,16 and moreover, the results of our
study showed statistical significant differences emphasizing
1052 M.-K. Breyer et al.considerable results. Another limitation is the lack of
a direct outcome and possible consequences of increased
levels of circulating leptin in COPD women. However, the
present study is the first to show gender related differences
in the adipose secretome system in COPD and further
research will lead to a better understanding of the precise
role of circulating leptin in COPD.
In conclusion, the results of the present study under-
score gender related differences in the systemic biology of
COPD. In men with clinically stable COPD, leptin, adipo-
nectin and resistin appear to be physiologically regulated,
while in women, leptin metabolism is likely altered. Leptin
secretion is increased in women with COPD when compared
to healthy women and compared to men with COPD,
particularly in overweight women with COPD. Moreover, the
present study confirms that subjects with COPD are char-
acterized by low-grade systemic inflammation reflected in
increased levels of CRP and IL-6.
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